Dr. Marty Makary (@DrMakaryFDA) on X (original) (raw)
Dr. Marty Makary
Dr. Marty Makary
- Pinned

TWO DAYS after receiving the application, FDA greenlit the new pancreatic cancer drug daraxonrasib for expanded access. This drug has also been granted a national priority voucher, which means a full application could be reviewed in a matter of weeks instead of 10-12 months.

Pregnant women shouldn't be left guessing about how approved drugs could affect their pregnancy. Our new FDA guidance is designed to help close that information gap.
The FDA is helping improve how safety data is collected for drugs & biologics used during pregnancy. Pregnant patients & their providers deserve clear, reliable information to make informed treatment decisions — and this final guidance is a step in the right direction.

A big improvement to FDA’s inspection toolkit.

People in healthcare are not afraid of hard work—in fact, they love it. It’s tedious tasks THAT DON’T MATTER that drive burnout.

Common sense health reforms can unite our country.

Proud moment for the FDA—the first real-time clinical trial!

Patients deserve a sense of urgency.

We’re deeply committed to reforming our IND/Phase 1 process. We must retain our position as the world leader in biotech.

FDA is investing in its scientific community.

American kids deserve healthier food — not an avalanche of drugs to manage symptoms.
- Dr. Marty Makary reposted

The FDA said it will allow some pancreatic cancer patients to receive access to a promising drug, even before it is officially approved. 
Great to be among fellow surgeons at
@AANSNeuro
. FDA is working hard to accelerate game-changing treatments and put the best tools possible in the hands of neurosurgeons.


Thank you American Association of Neurological Surgeons!!

Don't miss what's happening
People on X are the first to know.
